|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date01 Mar 1986 |
A Phase III, Randomized, Double Blind, Non-inferiority, Comparative Study of the New Transdermal Patch Dosage Form Containing Loxoprofen Sodium (100 mg) and Loxonin® (60 mg Tablet) for the Treatment of Acute Traumatic Injuries
This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - Daiichi-Sankyo) for the treatment of acute traumatic injuries.
100 Clinical Results associated with Daiichi Sankyo Brasil Farmacêutica Ltda.
0 Patents (Medical) associated with Daiichi Sankyo Brasil Farmacêutica Ltda.
100 Deals associated with Daiichi Sankyo Brasil Farmacêutica Ltda.
100 Translational Medicine associated with Daiichi Sankyo Brasil Farmacêutica Ltda.